Amber Gibson

Assistant Professor

The University of Texas MD Anderson Cancer Center Children's Cancer Hospital

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Amber Gibson is an Assistant Professor at The University of Texas MD Anderson Cancer Center Children's Cancer Hospital in the United States. Her research primarily focuses on novel therapeutic approaches for pediatric hematologic malignancies, including acute myeloid leukemia and Hodgkin lymphoma. Recent publications highlight her work on targeted therapies, post-transplant maintenance strategies, and the use of immunotherapeutic agents in young patients.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (5)

Jillian Gunther

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Samanta Catueno

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Koji Sasaki

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Michael Roth

Associate Professor of Pediatrics

The University of Texas MD Anderson Cancer Center Children's Cancer Hospital

UNITED STATES

View details

Jiasen He

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Amber Gibson

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies

Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia

Calasparagase Pegol Induced Hemolytic Anemia

Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia

Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen

Venetoclax use in a patient with ataxia telangiectasia and early T‐cell precursor acute lymphoblastic leukemia

Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience

Rare case of chronic lymphocytic leukemia in an adolescent treated with targeted therapy

Collaborators (5)

Jillian Gunther

Samanta Catueno

Koji Sasaki

Michael Roth

Jiasen He

Make your next move.